Abstract: Formulations and methods of use thereof that relate to biocompatible delivery of zinc protoporphyrin (ZnPP) are provided. In some embodiments, the ZnPP is formulated for oral delivery. Formulations may include microparticles of ZnPP, wherein the ZnPP active agent is admixed or coated with a pharmaceutically acceptable stabilizer providing for increased stability to acid conditions and improved solubility at neutral pH.

Abstract: Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. suspended in a carrier compatible with the tissue of interest, is topically applied to the surface of tissues at the site of anastomosis. The nanoparticles are comprised of the active agent and a pharmaceutically acceptable stabilizer.

Abstract: Methods of transdermally delivering a therapeutic amount of a triazole-triazolone compound are provided, e.g. for the prevention or treatment of basal cell carcinoma (BCC) in a subject. A therapeutic level of a triazole-triazolone compound such as itraconazole is delivered transdermally to a subject. Also provided are topical triazole-triazolone compositions that find use in practicing the subject methods.

Abstract: Improved methods are provided for the recombinant synthesis of collagen, particularly collagen VII, in host cell, and for therapeutic delivery of the same. The recombinant collagen is produced in a host cell that has increased levels of prolyl-4-hydroxylase, relative to basal cell levels. The collagen produced by the methods of the invention has increased numbers of modified proline residues, relative to a recombinant collagen produced in a host cell having basal levels of prolyl-4-hydroxylase. The increased proline modification provides for a collagen having increased stability, including increased in vivo stability.

Abstract: Disclosed are methods for the use of a truncated, recombinant laminin-511 for modifying hair growth as well as delivery devices, kits and methods for topically administering truncated, recombinant laminin-511. Furthermore disclosed are delivery devices, kits and methods using modulators of full-length laminin-511 expression or function to decrease hair growth in areas of unwanted hair growth.

Abstract: Compositions and methods are provided for the prevention and treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1? in the wound.

Abstract: Improved methods are provided for the recombinant synthesis of collagen, particularly collagen VII, in host cell, and for therapeutic delivery of the same. The recombinant collagen is produced in a host cell that has increased levels of prolyl-4-hydroxylase, relative to basal cell levels. The collagen produced by the methods of the invention has increased numbers of modified proline residues, relative to a recombinant collagen produced in a host cell having basal levels of prolyl-4-hydroxylase. The increased proline modification provides for a collagen having increased stability, including increased in vivo stability.

Abstract: Encompassed are pharmaceutically acceptable compositions formulated for the topical or transdermal delivery of probes specific for cyclooxygenase-2 (COX-2) of human and non-human subjects. In particular, an activatable probe comprises a fluorescent moiety comprising a fluorophore attached to a compound having selective affinity for COX-2, and a removable fluorescence quencher linked to the fluorescent moiety by a cleavable linker. Upon delivery to a recipient subject, the activatable probe is localized and concentrated in tissues and cells with elevated levels of COX-2. The linker is cleaved to release the fluorescence quencher.

Abstract: Disclosed are compositions, methods, and kits for joining together non-conjoined lumens in a patient's body including vascular lumens. More particularly, in various aspects, this invention provides compositions, methods, and kits for joining such non-conjoined lumens, including small lumens typically requiring microsurgical technique.

Abstract: Methods of treating Alzheimer's disease and other tauopathies are disclosed. In particular, the invention relates to methods of treating Alzheimer's disease and other tauopathies with inhibitors of microtubule affinity regulating kinase (MARK). Hyperphosphorylation of tau by MARK is associated with the pathogenic deposition of intracellular neurofibrillary tangles and loss of synaptic markers, dendritic spines, and synapses during progression of Alzheimer's disease and other tauopathies. Peptide inhibitors derived from the Helicobacter pylori protein CagA block phosphorylation of tau in neuronal cells and thereby decrease the deposition of neurofibrillary tangles and the toxic effects of Abeta-42.

Abstract: This disclosure relates generally to soft tissue augmentation threads, methods of making such threads and uses thereof, for example, in aesthetic applications (e.g., facial contouring, soft tissue augmentation products), surgery (e.g., sutures), drug delivery, negative pressure wound therapy, moist wound dressing, and the like.

Abstract: Pulmonary arterial hypertension (PAH) can be prevented in persons susceptible to the diseases and PAH patients can be treated by administering an effective dose of a leukotriene inhibitor. Suitable inhibitors include leukotriene A4 hydrolase (LTA4H) inhibitors, leukotriene B4 receptor (BLT1/BLT2) antagonists, 5-lipoxygenase (5-LO) inhibitors, and 5-lipoxgygenase activating protein (FLAP) inhibitors.

Abstract: This invention relates generally to threads of hyaluronic acid, methods of making such threads and uses thereof, for example, in aesthetic applications (e.g., facial contouring, dermal fillers), surgery (e.g., sutures), drug delivery, negative pressure wound therapy, moist wound dressing, and the like.

Abstract: Methods of transdermally delivering a therapeutic amount of a triazole-triazolone compound are provided, e.g. for the prevention or treatment of basal cell carcinoma (BCC) in a subject. A therapeutic level of a triazole-triazolone compound such as itraconazole is delivered transdermally to a subject. Also provided are topical triazole-triazolone compositions that find use in practicing the subject methods.

Abstract: An apparatus and method are provided for very precise and efficient delivery of e.g. viscous nutritive cell matrices and/or drugs into an exact point in the human body using minimally-invasive surgical techniques. Embodiments are compatible with modern catheter access and endoscopic techniques and a disposable-plus-capital-equipment business model separating the cost of the procedure between a reusable and a disposable component. It also represents a substantial step forward in terms of safety with no high voltage or high pressure components present in the body. The inherent risk of using this design to deliver substances into the human body is significantly reduced compared to standard hydraulic methods. Mechanical trauma associated with needles is avoided with this invention, and the method is also compatible with tortuous anatomy such as the coronary or brain arteries.

Abstract: Disclosed are compositions, methods, and kits for joining together non-conjoined lumens in a patient's body including vascular lumens. More particularly, in various aspects, this invention provides compositions, methods, and kits for joining such non-conjoined lumens, including small lumens typically requiring microsurgical technique.

Abstract: Disclosed are compositions, methods, and kits for joining together non-conjoined lumens in a patient's body including vascular lumens. More particularly, in various aspects, this invention provides compositions, methods, and kits for joining such non-conjoined lumens, including small lumens typically requiring microsurgical technique.

Abstract: Compositions and methods are provided for the manufacture and use of a pullulan-based collagen hydrogel film with controlled porosity. The hydrogel is fabricated with salt-induced phase inversion and cross-linking to form a reticular scaffold. This soft collagen scaffold displays excellent handling characteristics, durability, and a porous dermal-like ultrastructure that is maintained in vitro. Cells, including cells involved in tissue repair, are viably sustained within the scaffold. The hydrogel films are biodegradable, and find particular use in wound healing, where the hydrogel scaffold can be replaced by dermal cells over time.

Abstract: The present invention provides threads of hyaluronic acid, and/or derivatives thereof, methods of making thereof and uses thereof, for example, in aesthetic applications (e.g., dermal fillers), surgery (sutures), drug delivery, etc.

Abstract: Compositions and methods are provided for the treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1? in the wound. Agents that increase HIF-1? activity include, without limitation, agents that stabilize HIF-1?, e.g. deferoxamine, deferiprone, deferasirox, etc.; agents that upregulate expression of HIF-1?, e.g. dimethyloxalylglycine, etc., HIF-1? polypeptide or coding sequences; and combinations thereof. Such agents may be referred to herein as HIF-1? potentiating agents.